Request Deal Involvement
Samsung Biologics completed the acquisition of the remaining 50% stake in Samsung Bioepis from Biogen for $2.3bn.
Identify your role
Select the side you represented in this transaction, and provide your current job title.
Service Providers
legal advisors
Ropes & Gray
legal advisors
Lee & Ko
financial advisors
Moelis & Co
legal advisors
Kim & Chang
financial advisors
Citigroup
legal advisors
Linklaters
or
Principals
vendor
BIOGEN INC
target
SAMSUNG BIOEPIS
bidder
SAMSUNG BIOLOGICS
Principals or Service Provider not listed?Add missing Service Provider or Principal
Enter your Job Title on this deal
This title will appear on your profile next to this deal involvement.
To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:
All rights reserved. Copyright © 2025 Datasite